消化

订阅

MedSci主页 / 所有栏目 / 消化

NICE支持Braftovi治疗BRAF阳性转移性结直肠癌

2020-11-29 Allan MedSci原创

NICENICE指南BraftoviBRAF抑制剂BraftoviBRAF抑制剂Braftovi（encorafenib）BRAF阳性转移性结直肠癌
关注

英国国家健康与护理卓越研究所（NICE）支持Braftovi（encorafenib）联合cetuximab治疗BRAF阳性转移性结直肠癌。

英国国家健康与护理卓越研究所（NICE）支持Braftovi（encorafenib）联合cetuximab治疗BRAF阳性转移性结直肠癌。在发现成本效益估算较高后，NICE最初于9月拒绝了Braftovi（encorafenib）。但是，NICE现在已决定推荐该药物与cetuximab联用，用于以前接受过全身治疗的BRAF V600E突变阳性转移性结直肠癌（mCRC）成年患者。

NICE的决定是基于BEACON CRC Ⅲ期临床试验的结果，该结果表明Braftovi联合cetuximab可显著提高BRAF V600E突变型mCRC患者的中位总体生存率，并将死亡风险降低了39％。与对照组相比，联合治疗也产生了改善的客观缓解率。

Pierre Fabre英国和爱尔兰总经理Laura McMullin说：“我们很高兴NICE认识到Braftovi联合cetuximab对于这一高医疗需求人群的价值。我们要感谢英国NHS所做的努力，我们希望尽可能多的人将从这种创新治疗中受益”。

 

原始出处：

http://www.pharmatimes.com/news/nice_backs_braftovi_for_braf-positive_colorectal_cancer_1357546

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2021-11-04 3631173

    #Braftovi#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-12-01 fusion

    #NICE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-12-01 zhaojie88

    #BRAF#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-12-01 1249842em09(暂无昵称)

    #转移性#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-12-01 crystal0564

    #结直肠#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-12-01 仁者大医

    #FTO#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1941522, encodeId=45921941522e2, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Thu Nov 04 11:42:53 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289098, encodeId=19cb1289098be, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12792, encryptionId=077112e9237, topicName=NICE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743b215, createdName=fusion, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386680, encodeId=c91013866804f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453442, encodeId=f5e01453442f4, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478175, encodeId=34ff14e8175cc, content=<a href='/topic/show?id=54f7e7055b' target=_blank style='color:#2F92EE;'>#FTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7705, encryptionId=54f7e7055b, topicName=FTO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Dec 01 01:42:53 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903317, encodeId=2ee690331e87, content=**啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/928bf083b196415cbaa5a8292d70e333/cdfe5f3f34794434be595ee70b8766e8.jpg, createdBy=69a95401355, createdName=ms9000001235733856, createdTime=Sun Nov 29 16:33:07 CST 2020, time=2020-11-29, status=1, ipAttribution=)]
    2020-11-29 ms9000001235733856

    **啊

    0

相关资讯

因价格问题，NICE拒绝将罗氏的PD-L1单抗Tecentriq联合化疗用于广泛期小细胞肺癌

英国国家健康与护理卓越研究所（NICE）已发布指南草案，拒绝将罗氏的PD-L1单抗Tecentriq（atezolizumab）与卡铂和依托泊苷联合用于成人未经治疗的广泛期小细胞肺癌（SCLC）患者。该机构表示，虽然PD-L1抑制剂"符合NICE的标准，治疗可以延长患者的寿命的……但Tecentriq联合化疗的成本效益估算值高于NHS可接受的额度。"

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

NICE推荐将ustekinumab用于治疗对常规疗法或TNF-α抑制剂反应不足、失去反应和不耐受的中度至重度活动性溃疡性结肠炎（UC）的成人患者。

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

MSD和阿斯利康的抗癌药Lynparza（olaparib）已获得英国国家健康与护理卓越研究所（NICE）的适应症扩展用于某些癌症的维持治疗。

NICE拒绝了诺华的Adakveo（crizanlizumab）

血管阻塞现象和溶血是镰状细胞病（SCD）的临床特征，SCD是一种纯合性异常血红蛋白[血红蛋白S(hemoglobin S, HbS)]遗传病。血管阻塞可导致反复疼痛发作（以前称为镰状细胞危象），以及各

NICE推荐将血小板生成素受体激动剂Doptelet用于肝病手术前使用

英国国家卫生与医疗保健研究院（NICE）已发布新的指南草案，建议将Dova Pharmaceuticals的血小板生成素受体激动剂Doptelet（avatrombopag）用于具有血小板减少症或血小板计数低的、需要手术的慢性肝病患者。

NICE支持Rinvoq治疗严重的活动性类风湿关节炎

英国国家健康与护理卓越研究所（NICE）已向患有严重活动性类风湿关节炎（RA）的患者推荐了AbbVie公司的Rinvoq（upadacitinib）。

拓展阅读

eGastroenterology：脂肪变性不会增加转移性结直肠癌的化疗肝损伤风险

本文通过回顾性分析探讨基线肝脂肪变性是否会增加MCRC中CALI风险，为MCRC个体化管理策略提供新证据。

读书报告 | CheckMate 8HW研究：纳武利尤单抗联合伊匹木单抗治疗高度微卫星不稳定（MSI-H）转移性结直肠癌

在未接受过针对转移全身治疗的MSI-H/dMMR转移性结直肠癌患者中，纳武利尤单抗联合伊匹木单抗双免治疗方案，与化疗相比，PFS显著延长。

CCR：血液ctDNA预测转移性结直肠癌一线化疗疗效，大panel和多次采样可提高准确性

研究者旨在一个前瞻性队列研究中，检验使用ctDNA监测来评估接受一线化疗联合抗VEGF或抗EGFR抗体治疗的mCRC患者的早期治疗反应和临床结局，探索其中的前景与挑战。

肠癌初始治疗怎办？抗癌药SHR-1701联合标准治疗方案，60%患者病灶大幅度缩小超过30%!

转移性结直肠癌治疗选择有限、死亡率高，新治疗理念需求迫切，免疫检查点抑制剂虽改善部分患者生存期但适用人群有限，SHR - 1701 等联合治疗展现出较好疗效，为改善现状带来希望。

STTT | SHR-1701联合XELOX和贝伐珠单抗一线治疗不可切除转移性结直肠癌的疗效和安全性

该研究旨在评估SHR-1701联合XELOX化疗和贝伐珠单抗作为mCRC患者一线治疗的疗效和安全性，SHR-1701联合XELOX化疗和贝伐珠单抗在不可切除mCRC患者中表现出良好的疗效和可控安全性。

三氟尿苷/替吡嘧啶 (FTD/TPI)治疗晚期肠癌近3年，这是特例吗？

介绍晚期转移性结直肠癌治疗进展，以一患者为例，其三线用 FTD/TPI 治疗近 3 年且仍有效，讨论三线治疗该药的可能性。